Norry practiced adult internal medicine at Abington Memorial Hospital in Abington, Pennsylvania for 13 years. Prior to his work in the biotech and pharmaceutical industries, Dr. Prior to joining Adaptimmune, he served as Safety Development Leader and was Chair of the Hepatic Safety Panel at GSK. He has been acting Chief Medical Officer since August 2019. Norry has served as Head of Clinical Safety and Pharmacovigilance and leader of the ADP-A2AFP program since 2015. “In addition, we have made changes to our R&D leadership to accelerate how our products move from research to late stage development, including rapid application of translational learnings that are crucial to bringing cell therapies to patients.”ĭr. I look forward to continuing to work with Elliot to deliver cell therapy treatments to patients with cancer,” said Adrian Rawcliffe, Adaptimmune’s Chief Executive Officer. This builds on his impact leading the ADP-A2AFP program in liver cancer as well as leading our safety and pharmacovigilance team over the last four years. “Elliot has done a fantastic job as acting CMO over the past few months. Elliot Norry as Senior Vice President and Chief Medical Officer (CMO) effective immediately, and additional changes to its R&D organization. 13, 2020 (GLOBE NEWSWIRE) - Adaptimmune Therapeutics plc ( ADAP), a leader in cell therapy to treat cancer, today announced the appointment of Dr. PHILADELPHIA and OXFORDSHIRE, United Kingdom, Jan. Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic candidates and trials
0 kommentar(er)
